Drug combo aims at genetic weaknesses in head and neck cancer
Disease control
Completed
This early-stage trial tested a combination of two oral drugs, tipifarnib and alpelisib, in 45 adults with recurrent or metastatic head and neck squamous cell carcinoma that has specific genetic changes (HRAS overexpression or PIK3CA mutations). The goal was to find a safe dose a…
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC